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Abstract
Severe combined hyperlipidaemia has occasionally been associated with infiltration of tissues in
addition to arteries and the skin. We report a woman with Type 2 diabetes mellitus (DM) and
severe combined hyperlipidaemia who developed retinal lipid infiltration, resulting in blindness. A
61-year-old woman with a 15-year history of Type 2 DM was admitted following a two-week
history of progressive visual loss. Examination identified lipid infiltration into the retina.
Phenotypically she had severe combined hyperlipidaemia with elevated IDL cholesterol and a broad
beta band on lipoprotein electrophoresis, raising the possibility of familial dysbetalipoproteinaemia.
However, gene sequencing analysis indicated that the patient was homozygous for the E3/E3 allele
of the ApoE gene with no mutations detected in either the coding region or intron-exon
boundaries. Her lipid profile improved following dietary therapy and gemfibrozil treatment, but this
had little effect on either her fundal appearances or her visual acuity. Type 2 DM plays a vital role
both in allowing expression of severe combined hyperlipoproteinaemia, in addition to serving as a
risk factor for complications such as tissue infiltration.
Findings
Severe combined hyperlipidaemia with comparable eleva-
tion of both triglycerides and cholesterol usually has an
inherited basis, such as familial dysbetalipoproteinaemia.
The expression of the genetic potential for these lipid dis-
orders is a complex process which only occurs when
genetically inherited predisposing factors interact with
other metabolic factors that exacerbate hyperlipidaemia.
The integral genetic factor in familial dysbetalipoprotein-
aemia is the presence of abnormal apolipoprotein E
(apoE) which binds defectively to hepatic receptors and
impairs clearance of intermediate density lipoproteins
(IDL) and dense very low density lipoproteins (VLDL)
from the circulation [1]. Familial combined hyperlipidae-
mia is characterised by overproduction of apolipoprotein
B (apo B) containing particles by the liver, but there is no
diagnostic genetic test. Severe combined hyperlipidaemia
from both these causes is associated with arterial wall
lipid infiltration and atherosclerosis while familial dysbe-
talipoproteinaemia in particular, has been reported to
cause infiltration of other tissues. This report describes a
patient with Type 2 diabetes mellitus (DM) who devel-
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oped a new complication of severe combined hyperlipi-
daemia in which lipid infiltrated into the retina, resulting
in blindness.
A 61 year old woman with Type 2 DM of 15 years dura-
tion, complicated by hypertension and aortic incompe-
tence was admitted following a 2 week history of
progressive loss of vision in her left eye. The patient's Type
2 DM had been managed with diet alone, up until 6
months prior to admission when gliclazide therapy was
prescribed. Home glucose monitoring revealed blood glu-
cose levels in the range 4–9 mmol/l before meals. Other
relevant past medical history included the removal of cat-
aracts 9 months previously and a single course of laser
therapy to each eye for retinopathy. Her hypertension had
been well controlled by the calcium channel antagonist,
felodipine. The aortic incompetence was secondary to
rheumatic heart disease and culminated in a presentation
with pulmonary oedema. She ultimately required an aor-
tic valve replacement with a mechanical prosthesis 2 years
before presentation. A single coronary artery graft (cir-
cumflex artery) was performed at the time, although she
never suffered from any symptoms of angina. She was
subsequently maintained on digoxin, frusemide and war-
farin.
Examination on admission revealed no evidence of any
cutaneous stigmata of lipid disorders. Visual acuity was
reduced to counting fingers in the left eye. Her fundal
appearance in that eye was abnormal with gross exudative
and haemorrhagic change (Figure 1a). Acuity in the right
eye was reduced to perception of light, and fundoscopy
revealed a vitreous opacity consistent with a vitreous
haemorrhage.
Lipid, biochemical and haematological evaluation are
outlined in Table 1. The most significant abnormalities
evident were combined hyperlipidaemia and marked pro-
teinuria (Table 1). Lipoprotein electrophoresis was per-
formed according to the manufacturer's instructions
(Beckman Coulter, CA, USA) and stained with Sudan
Black 7B. A "broad beta band" was revealed, such as that
found characteristically in familial dysbetalipoproteinae-
mia (Figure 1b). Apolipoprotein E phenotyping was
determined as described previously [2]. Differentiation
between the common apolipoprotein E genetic polymor-
phisms (apoE2, E3, E4) was performed as described by
Hixson and Vernier [3]. The patient was homozygous for
the E3/E3 allele of the Apo E gene. The exons and their
flanking regions of the patient's ApoE gene were
sequenced using Big Dye Dideoxy Terminator Chemistry
(Applied Biosystems, CA, USA). All coding regions and all
intron-exon splice junctions of the patient's ApoE were
identical with the published sequence [4], and no ambi-
guities or potentially heterozygous base positions were
detected. One difference however was detected in the
intronic sequence of the patient compared with the pub-
lished sequences (Intron A, base 69: C substituted for G)
[4].
The patient's proteinuria was investigated with a renal
biopsy in order to exclude lipid infiltration into the kid-
ney as this had occurred in a patient with familial dysbe-
talipoproteinaemia who had presented with proteinuria
[5]. The biopsy showed changes consistent with diabetic
nephropathy, with little evidence of foam cells to suggest
a lipid infiltrative process. Haematological evaluation
showed that the patient was pancytopenic (Table 1). Bone
marrow aspiration and trephine biopsy revealed no evi-
dence of marrow infiltration or aplasia, and a peripheral
destructive process was thereby inferred. Since it was felt
that her gliclazide might have been contributing to this
process, this treatment was ceased. Subsequent blood
counts showed significant resolution of the pancytopenia,
with haemoglobin stabilising at 10.2 g/dL, white cell
count at 3.0 × 109/L and platelets at 259 × 109/L, changes
that coincided with improvement of her severe hyperlipi-
daemia.
The extent of the confluent retinal exudates and haemor-
rhages was felt to be significantly more severe than would
be expected in typical diabetic retinopathy. A fluorescein
angiogram revealed evidence of diffuse capillary leakage,
but no evidence of neovascularisation. In order to investi-
gate her retinal abnormalities further, a vitreous biopsy of
the left eye was performed. This revealed a lipid infiltrate
which on electrophoresis was demonstrated to be com-
posed of IDL (Figure 1c). Since the vitreous lies anatomi-
cally adjacent to the retina, it was therefore surmised that
the exudative retinal changes were secondary to an infil-
tration by IDL.
Further treatment included intensive dietary therapy, and
subsequently gemfibrozil treatment, at a dose of 600 mg
b.d. One month later, her cholesterol level was 10.9
mmol/L with triglycerides 6.6 mmol/L. Two months later
she was admitted to another hospital with a separate ill-
ness. At this time, her lipid profile had improved substan-
tially, with plasma cholesterol 5.3 mmol/L and
triglycerides 2.6 mmol/L.
She had a vitrectomy performed on the right eye, but this
procedure resulted in minimal improvement in her
vision. Improvement in her lipid profile had little effect
on either her fundal appearances or her visual acuity in
the left eye.
Marked elevation of both cholesterol and triglyceride lev-
els to above 10 mmol/L is very likely to indicate the pres-
ence of a genetic abnormality that increases hepaticLipids in Health and Disease 2006, 5:29 http://www.lipidworld.com/content/5/1/29
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production of apo B containing lipoprotein particles or
decreases the metabolism of these particles, combined
with a metabolic abnormality that exacerbates the inher-
ited defect. The broad beta band on lipoprotein electro-
phoresis in this patient is characteristically found in
familial dysbetalipoproteinaemia, but may also be
present in other subjects with severe combined hyperlipi-
daemia. Prior to the availability of apo E phenotyping and
genotyping, criteria of VLDL-cholesterol/serum triglycer-
ide ratio >0.69 and VLDL-cholesterol/VLDL-triglyceride
ratio >0.92 were used to define the presence of VLDL rem-
nants and familial dysbetalipoproteinaemia [6,7].
In this patient the ratios did not meet these criteria and
phenotyping, genotyping and gene sequencing did not
show any abnormality of apo E. It is therefore not possible
to sustain the diagnosis of familial dysbetalipoproteinae-
mia, despite the presence of a broad beta band. The find-
ings could be consistent with severe familial combined
hyperlipidaemia, which is characterised by hepatic over-
production of apo B containing particles. However, there
is no specific diagnostic test for this condition.
Type 2 DM is commonly associated with dyslipidaemia,
particularly elevation of VLDL triglyceride and reduction
of HDL cholesterol. Overproduction of VLDL particles has
been well documented and this metabolic abnormality is
likely to exacerbate the combined hyperlipidaemia associ-
ated with the inherited disorders of familial dysbetalipo-
proteinaemia and familial combined hyperlipidaemia.
Diabetes has been suggested as a prominent cofactor for
the development of familial dysbetalipoproteinaemia for
a number of years. Studies such as those by Eto et al [8] are
in accordance with the proposal that Type 2 DM is a
a) Photographs of the patient's eye showing gross exudative and haemorrhagic change, b) Serum lipid profile showing a broad  beta band detected in the patient's serum collected on two different days; lane 1: Patient sample #1; lane 2: Patient sample #2;  lane 3: control, c) Lipid profile from vitreous material obtained from patient's eye showing faint staining for Intermediate Den- sity Lipoprotein (IDL); lane 1: control; lane 2: Patient sample Figure 1
a) Photographs of the patient's eye showing gross exudative and haemorrhagic change, b) Serum lipid profile showing a broad 
beta band detected in the patient's serum collected on two different days; lane 1: Patient sample #1; lane 2: Patient sample #2; 
lane 3: control, c) Lipid profile from vitreous material obtained from patient's eye showing faint staining for Intermediate Den-
sity Lipoprotein (IDL); lane 1: control; lane 2: Patient sample.Lipids in Health and Disease 2006, 5:29 http://www.lipidworld.com/content/5/1/29
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prominent risk factor for the development of elevated
lipid levels in patients with apoE2/E2. Furthermore, in the
present case, the heavy proteinuria which occurred as a
result of diabetic nephropathy is also likely to have played
a significant role as a cofactor for the expression of severe
combined hyperlipidaemia. Proteinuria is associated with
hyperlipidaemia when it reaches nephrotic range and in
this case may be a consequence of excess hepatic VLDL
secretion. Therefore, the Type 2 DM is likely to have had a
dual role in the expression of the combined hyperlipidae-
mia.
Infiltration of arterial wall tissue by lipoproteins, causing
atherosclerosis and vessel narrowing, is a common com-
plication of severe combined hyperlipidaemia. Infiltra-
tion of dermal tissue by lipids causes xanthomata and is
well described as occurring in the combined hyperlipidae-
mia associated with familial dysbetalipoproteinaemia.
There have also been reports of lipid deposition in kidney,
splenic and bone marrow tissue in this condition [5,9].
Deposition of lipoproteins in retinal tissue is very unusual
and in this patient occurred in the setting of marked ele-
vation of cholesterol and triglyceride, carried in relatively
dense VLDL particles and IDL particles, but not associated
with abnormal apo E.
Type 2 DM may have also played a role in the retinal infil-
tration of lipids seen in this patient. Lipid accumulation in
renal glomeruli has been previously described in patients
with familial dysbetalipoproteinaemia who were known
to have Type 2 DM or who were diagnosed with Type 2
DM within six months and presented with proteinuria
[5,9]. Furthermore, reduction of serum lipids with lipid
lowering drugs in patients with Type 2 DM, diabetic mac-
ulopathy and hyperlipidaemia has been shown to result
in a dramatic regression of retinal hard exudates [10]. In
contrast, improvement in the current patient's lipid pro-
file had little effect on the fundal appearance or visual acu-
ity of the eye. Lipid infiltration into the retina associated
with severe combined hyperlipidaemia however, is
extremely unusual. It seems highly likely that one of the
principal causes of lipid accumulation in the retina is the
increased endothelial permeability that is associated with
microvascular disease in diabetic patients. The haemor-
Table 1: Lipid, Biochemical and Haematological Evaluation.
Lipid Profile Value Reference Range
Total cholesterol 10.6 mmol/L <5.5 mmol/l
Total triglyceride 7.5 mmol/L <2.0 mmol/1
HDL cholesterol 0.97 mmol/L <0.9–2.4 mmol/l
LDL cholesterol 6.6 mmol/L <3.5 mmol/l
VLDL cholesterol 3.0 mmol/L <0.5 mmol/l
VLDL triglyceride 5.6 mmol/L <1.0 mmol/l
IDL cholesterol 2.9 mmol/L
IDL triglyceride 0.8 mmol/L
Apo A1 151 mg/dL 125–198 mg/dL
Apo B 297 mg/dL 31–151 mg/dL
ApoB/Apo A1 1.97 mg/dL 0.21–0.73 mg/dL
ApoE genotyping E3/E3
Biochemical Evaluation Value Reference Range
Urea 9.6 mmol/L 3.1–8.8 mmol/L
Creatinine 0.13 mmol/L 0.07–0.11 mmol/L
Albumin 31 g/L 35–50 g/L
24 hr urinary protein 3.8 g/day 0.00–0.08 g/day
Thyroid function Normal
Hb A1C 7.7% <7.0%
Haematological Evaluation Value Reference Range
Haemoglobin 8.2 g/dL 11.5–16.5 g/dL
White cell count 2.4 × 109/L 4.0–11.0 × 109/L
Platelets 121 × 109/L 150–450 × 109/L
Auto antibodies Negative
Rheumatoid factor Negative
Anti nuclear factor Negative
Anti neutrophil cytoplasmic antibody NegativePublish with BioMed Central    and   every 
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rhagic changes in the retina that were observed in this case
are likely to have arisen from the combination of
increased endothelial permeability and anticoagulation
with warfarin.
An additional contributing factor to the pathogenesis in
this case could also be abnormal lipid metabolism,
thereby increasing the patient's susceptibility to forming
lipid deposits within the eye. It has recently been demon-
strated that lipoproteins isolated from the Bruch's mem-
brane differ significantly from plasma lipoproteins and
that the genes for apoB and apoA-I are expressed within
the eye [11]. These data suggest that the retinal pigment
epithelium assembles and secretes large alipoprotein par-
ticles. Furthermore, studies in mice over-expressing ApoB
suggest that hyperlipidemia predisposes mice to the for-
mation of basal laminar deposits by altering hepatic and/
or retinal pigment epithelium lipid metabolism [12].
This case is unusual in a number of respects. Firstly, it rep-
resents an uncommon complication of any lipid disorder,
with tissue infiltration by lipid. Secondly, despite a phe-
notype that resembled familial dysbetalipoproteinaemia,
the ApoE genotype of this patient was E3/E3, and not the
E2/E2 genotype associated with this disease. Furthermore,
this case emphasises how Type 2 DM and associated pro-
teinuria can act as prominent metabolic cofactors to exac-
erbate combined hyperlipidaemia and precipitate tissue
infiltration.
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